Lung Cancer Program

我正在招聘基础研究人员到实验室工作。主要研究领域是非小细胞肺癌对EGFR抑制剂的耐药机制，以及通过干扰阻止细胞凋亡的分子（Bcl-2家族和细胞凋亡抑制蛋白）来调节细胞凋亡。将测试具有逆转或规避对EGFR抑制剂耐药潜力的新分子，并阐明其作用机制。特别是，热蛋白90抑制剂的研究显得特别有前景。基于之前在切除的非小细胞肺癌样本中的工作，我们确定了HSP-90是一个重要的预后标志物，也是一个重要的体外治疗靶点，新的HSP-90抑制剂将在我之前开发的体外筛选系统中进行测试。在临床中，我正在建立所有胸部恶性肿瘤的临床研究，包括肺癌（非小细胞肺癌和小细胞肺癌），间皮瘤，胸腺瘤和食管癌。临床开发的重点是新药的早期开发，特别是那些对EGFR抑制剂和细胞凋亡调节剂难治的患者有效的药物。即将开放的是Bcl-2小分子抑制剂在小细胞肺癌中的II期研究，这是一种用于厄洛替尼治疗失败的晚期非小细胞肺癌患者的第二代EGFR不可逆抑制剂。正在组织一个肿瘤委员会，包括主要器官专家。下一阶段将包括在临界可手术非小细胞肺癌和食管癌新辅助治疗领域的多学科研究。此外，我正在重组跨研究所肺癌小组，以促进合作和新项目的范围。其中之一将是肺癌干细胞的发展。

I am in the process or recruitment for basic researchers to work in the laboratory. The main areas of research are mechanisms of resistance to EGFR inhibitors in non-small cell lung cancer, and modulation of apoptosis by interfering with molecules that prevent apoptosis (Bcl-2 family and inhibitor of apoptosis proteins). Novel molecules that have the potential of reversing or circumventing resistance to EGFR inhibitors will be tested and the mechanism of action elucidated. In particular, the study of HSP-90 inhibitors appear particular promising. Based on previous work in resected non-small cell lung cancer samples, where we identified HSP-90 to be an important prognostic marker and also an important target for therapy in vitro, novel HSP-90 inhibitors will be tested in an in vitro screening system that I developed previously. In the clinic, I am setting up clinical studies in all malignancies of the chest, including lung cancer (non-small cell and small cell lung cancer), mesothelioma, thymoma and esophageal cancers. The emphasis in clinical development is on early phase development of novel agents, in particular those that can be effective in patients who are refractory to EGFR inhibitors and modulators of apoptosis. Of immediate opening are phase II studies of a Bcl-2 small molecule inhibitor in small cell lung cancer, a second-generation EGFR irreversible inhibitor in patients with advanced non-small cell lung cancer who failed erlotinib. A tumor board is being organized, to include major organ specialists. The next phase will include activation of multidisciplinary studies in the area of neoadjuvant treatment of borderline operable non-small cell lung cancer and esophageal cancer. Furthermore, I am reorganizing the cross institute lung cancer group, with the scope of fostering collaborations and novel project. One of these will be on the development of lung cancer stem cells.